Encapsulate Bio vs Saluda Medical

Side-by-side comparison of AI visibility scores, market position, and capabilities

Saluda Medical leads in AI visibility (74 vs 35)
Encapsulate Bio logo

Encapsulate Bio

EmergingLife Sciences & BioTech

Tumor-on-a-Chip Personalized Cancer Therapeutics

Encapsulate Bio develops tumor-on-a-chip microfluidic platforms that test patient-derived tumor samples against cancer therapies to guide personalized treatment selection; early-stage biotech focused on ex vivo drug sensitivity testing for oncology.

AI VisibilityBeta
Overall Score
D35
Category Rank
#128 of 198
AI Consensus
86%
Trend
stable
Per Platform
ChatGPT
33
Perplexity
37
Gemini
31

About

Encapsulate Bio is an early-stage biotechnology company focused on advancing personalized cancer medicine through its proprietary tumor-on-a-chip platform. The technology creates miniaturized, microfluidic three-dimensional models of patient-derived tumors — capturing the complex cellular architecture and microenvironment of real cancer tissue — and exposes these microtumors to panels of therapeutic agents to generate rapid, clinically relevant drug sensitivity data. The goal is to give oncologists predictive, patient-specific treatment guidance before committing to a full course of chemotherapy or targeted therapy, reducing the trial-and-error approach that currently characterizes much of oncology treatment selection.

Full profile
Saluda Medical logo

Saluda Medical

LeaderLife Sciences & BioTech

Neuromodulation & Spinal Cord Stimulation

Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.

AI VisibilityBeta
Overall Score
B74
Category Rank
#10 of 198
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
72
Perplexity
68
Gemini
80

About

Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.

Full profile

AI Visibility Head-to-Head

35
Overall Score
74
#128
Category Rank
#10
86
AI Consensus
73
stable
Trend
stable
33
ChatGPT
72
37
Perplexity
68
31
Gemini
80
35
Claude
71
35
Grok
71

Key Details

Category
Tumor-on-a-Chip Personalized Cancer Therapeutics
Neuromodulation & Spinal Cord Stimulation
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.